Assessment of Patients With Hereditary Transthyretin Amyloidosis – Understanding the Impact of Management and Disease Progression

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis - United Kingdom
doi 10.1080/13506129.2019.1627312
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Pnd156 - The Impact of Hereditary Transthyretin Amyloidosis (Hattr) on Work: The Patients’ Perspectives

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Impact of Patisiran, an RNAi Therapeutic, on Orthostatic Intolerance in Patients With Hereditary Transthyretin-Mediated Amyloidosis

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Alnylam Act®: Heterogenous Disease Manifestations of Hereditary Transthyretin-Mediated Amyloidosis

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Identifying Mixed Phenotype: Evaluating the Presence of Polyneuropathy in Patients With Hereditary Transthyretin-Mediated Amyloidosis With Cardiomyopathy

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis

Journal of Clinical Pharmacology
Pharmacology
2019English

Diagnostic Challenges in Hereditary Transthyretin Amyloidosis With Polyneuropathy: Avoiding Misdiagnosis of a Treatable Hereditary Neuropathy

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2017English

Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers

Neurology and Therapy
Neurology
2018English

The V122I Mutation in Hereditary Transthyretin-Mediated Amyloidosis Is Significantly Associated With Polyneuropathy

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Hereditary ATTR Amyloidosis With Cardiomyopathy Caused by the Novel Variant Transthyretin Y114S (p.Y134S)

Internal Medicine
Internal MedicineMedicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy